Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2024 Mar 25.
Published in final edited form as: J Am Board Fam Med. 2023 Feb 8;36(1):25–38. doi: 10.3122/jabfm.2022.220143R1

Expert Consensus Statement on Proficiency Standards for Dermoscopy Education in Primary Care

Tiffaney Tran 1, Peggy R Cyr 1, Alex Verdieck 1, Miranda D Lu 1, Hadjh T Ahrns 1, Elizabeth G Berry 1, William Bowen 1, Ralph P Braun 1, Joshua M Cusick-Lewis 1, Hung Q Doan 1, Valerie L Donohue 1, Deborah R Erlich 1, Laura K Ferris 1, Evelyne Harkemanne 1, Rebecca I Hartman 1, James Holt 1, Natalia Jaimes 1, Timothy A Joslin 1, Zhyldyz Kabaeva 1, Tracey N Liebman 1, Joanna Ludzik 1, Ashfaq A Marghoob 1, Isac Simpson 1, Jennifer A Stein 1, Daniel L Stulberg 1, Isabelle Tromme 1, Matthew J Turnquist 1, Richard P Usatine 1, Alison M Walker 1, Bryan L Walker 1, Robert F West 1, Megan L Wilson 1, Alexander Witkowski 1, Dominic J Wu 1, Elizabeth V Seiverling 1, Kelly C Nelson 1
PMCID: PMC10961604  NIHMSID: NIHMS1973672  PMID: 36759132

Abstract

Background:

Primary care providers (PCPs) frequently address dermatologic concerns and perform skin examinations during clinical encounters. For PCPs who evaluate concerning skin lesions, dermoscopy (a noninvasive skin visualization technique) has been shown to increase the sensitivity for skin cancer diagnosis compared with unassisted clinical examinations. Because no formal consensus existed on the fundamental knowledge and skills that PCPs should have with respect to dermoscopy for skin cancer detection, the objective of this study was to develop an expert consensus statement on proficiency standards for PCPs learning or using dermoscopy.

Methods:

A 2-phase modified Delphi method was used to develop 2 proficiency standards. In the study’s first phase, a focus group of PCPs and dermatologists generated a list of dermoscopic diagnoses and associated features. In the second phase, a larger panel evaluated the proposed list and determined whether each diagnosis was reflective of a foundational or intermediate proficiency or neither.

Results:

Of the 35 initial panelists, 5 PCPs were lost to follow-up or withdrew; 30 completed the fifth and last round. The final consensus-based list contained 39 dermoscopic diagnoses and associated features.

Conclusions:

This consensus statement will inform the development of PCP-targeted dermoscopy training initiatives designed to support early cancer detection. (J Am Board Fam Med 2023;36:25–38.)

Keywords: Continuing Medical Education, Delphi Method, Dermoscopy, Expert Opinion, Focus Groups, General Practitioners, Melanoma, Primary Care Physicians, Primary Health Care, Skin Cancer

Background

Skin cancer is the most common cancer in the United States, and the 3 major types are basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. While most BCCs and SCCs are treatable and curable, melanoma is fatal when detected at advanced stages.1,2 Delays in diagnosis and treatment can be caused by lack of timely recognition exacerbated by poor access to dermatology specialists for evaluation of skin lesions. In the United States, these access disparities occur along the lines of patient socioeconomic status, race/ethnicity, and rural residence.3,4 In regions with barriers to dermatology access, trained primary care providers (PCPs) including advanced practice practitioners, such as physician assistants and nurse practitioners, play an important role in the detection, diagnosis, and management of skin cancer.5

For the early detection of skin cancer, clinical skin examinations are 1 of the safest and most cost-effective screening interventions available to patients.6 Skin examinations may be performed unassisted (with the naked eye) or with dermoscopy, a visualization technique involving use of a dermatoscope. A dermatoscope is a handheld instrument consisting of a magnifier and a polarized light source that enables detailed examination of surface and subsurface features not discernible by the naked eye.7 Dermoscopy use results in a higher diagnostic accuracy for melanoma detection compared with unassisted examinations.8 In a large meta-analysis of 104 published studies, dermoscopy was shown to significantly improve both the sensitivity and specificity for melanoma diagnosis when compared with visual inspection alone.9 This significantly reduces the number of melanomas overlooked and the number of benign lesions unnecessarily biopsied in the course of identifying melanoma, reducing patient morbidity and mortality.

On the frontline of health care delivery, PCPs frequently address dermatologic problems and perform skin examinations,10 and an estimated 12% to 25% of primary care encounters address a patient’s dermatologic problem.11,12 In a population-based study, 65.1% of patients presenting to their PCPs with skin-related issues did not seek further dermatologic care from a dermatologist or other health care provider that year.11 For patients at risk for skin cancer, each of these encounters in the primary care setting represents an opportunity to detect skin cancer at an early stage.

Among PCPs who treat skin conditions, appropriate training in the dermoscopic evaluation of skin lesions has been shown to improve their diagnostic sensitivity for skin cancer, including melanoma.1317 To gain proficiency in dermoscopy, clinicians must become familiar with the dermoscopic features (eg, colors, structures, patterns) of common dermatologic diagnoses.18 The recognition of these features supports a clinician’s decision of whether to biopsy, refer, or offer reassurance.

Before this study, no formal consensus existed on the fundamental competencies that PCPs should have with respect to dermoscopy for skin cancer detection.19,20 While a foundational dermoscopy proficiency standard has been developed for dermatology residents,21 the practice needs of PCPs differ from those of dermatologists, warranting a focused effort tailored to the primary care context. Therefore, the objective of this study was to develop an expert consensus statement on proficiency standards for PCPs learning or using dermoscopy.

To achieve this, the research team coordinated a modified Delphi exercise, an iterative method commonly used to obtain consensus opinion from a group of subject matter experts.22,23 For each proficiency standard, the expert panel determined which diagnoses and features are important for PCPs to identify, informing learner expectations for dermoscopy educators. In seeking agreement on specific competencies, this study will also establish content validity24 for PCP-targeted dermoscopy training programs and proficiency assessments.

Methods

Study Design

This study received approval from the MD Anderson Cancer Center Institutional Review Board (Protocol #2020–0667). The consensus process, as shown in Figure 1, used a 2-phase modified Delphi method for both the diagnoses and features stages. In the first phase, a smaller focus group generated a preliminary statement, and in the second phase, a larger panel refined the proposed statement through a controlled feedback process.21 This structured method guarantees that outcomes most closely represent the collective viewpoints of the group.22,23 To ensure anonymity of panelists, the research team administered electronic surveys using the web-based platform REDCap (Version 12.2.6, Vanderbilt University, Nashville, TN).

Figure 1.

Figure 1.

Consensus process using a 2-phase modified Delphi method.

This consensus process was organized as 2 successive stages: (1) a diagnoses survey series, and (2) a features survey series. To steer the consensus process, a focus group of 5 experts was assembled: 3 PCPs (PRC, AV & MDL) who routinely use dermoscopy in clinical practice and 2 pigmented lesion experts (EVS & KCN) who are highly engaged in PCP dermoscopy training initiatives. The focus group convened virtually before each survey series to propose, discuss, and approve survey items.

For the diagnoses survey series, the objective was to create an expert-approved list of common dermatologic diagnoses with characteristic dermoscopic features that should be included in dermoscopy training for PCPs. In the initial round, the panel reviewed a proposed list of diagnoses developed by the focus group. Most items on the list were drawn from a prior modified Delphi study that generated a foundational dermoscopy proficiency standard for dermatology residents.21 Contributors to this prior effort included members of the Melanoma Prevention Working Group–Pigmented Lesion Subcommittee (MPWG-PLS, affiliated with the Southwest Oncology Group and the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network) and other pigmented lesion experts.21

The proposed list was divided into 5 categories: nonmelanocytic lesions, benign melanocytic lesions, melanoma, special sites, and other diagnoses such as skin infections and infestations.21 This last category encompassed additional diagnoses (eg, verruca, molluscum contagiosum) that PCPs frequently encounter in clinical practice. Given the range of interest in and engagement with dermoscopy among PCPs, panelists were asked to assign each diagnosis to 1 of the following 3 options:

  • Level 1 (foundational): Clinicians who desire a basic yet practical understanding of dermoscopy and its application for skin cancer detection should be able to recognize these diagnoses with basic training.

  • Level 2 (intermediate): More experienced clinicians who are highly interested in learning dermoscopy beyond level 1 should be able to recognize these diagnoses. With adequate training, recognition of these “above and beyond” diagnoses would demonstrate an additional level of mastery beyond level 1. Diagnoses that do not reach consensus for inclusion in level 1 may be considered for inclusion in level 2.

  • Neither level 1 nor level 2: Recognition of these diagnoses using dermoscopy would not reflect either foundational or intermediate dermoscopy proficiency for PCPs. This may include diagnoses that are extremely rare in the population or that are especially challenging to diagnose, even by advanced dermoscopy users.

For each diagnosis, panelists rated how strongly they agreed or disagreed (via a 5-point Likert scale) with its inclusion in level 1, level 2, or neither. Panelists were also able to provide written feedback or suggest additional diagnoses to be presented in the next round. In subsequent rounds, panelists rerated diagnoses that nearly reached consensus for inclusion at a particular level (positive responses from >50% to 60% but <70% of participating panelists). Panelists also assigned additional diagnoses to level 1, level 2, or neither. Three formal rounds of surveys were performed between October and December 2021 until all diagnoses received a consensus-based assignment.

For the features survey series, the objective was to develop an expert-approved list of dermoscopic features for each included diagnosis. The aim was to capture features that are highly characteristic and important to recognize and that should be included in PCP dermoscopy education. Commonly seen structures may be included even if not specific to that diagnosis.

Based on a literature review, a proposed list of features was developed by the steering committee and presented to the panel. References for this list included the MPWG-PLS consensus on dermoscopy proficiency expectations for dermatology residents,21 the Dermoscopedia website,25 the 2016 International Dermoscopy Society consensus on dermoscopy terminology,26 the International Skin Imaging Collaboration dictionary of standardized terms, and other medical literature on PubMed, as documented in the online appendices.

For each feature, panelists rated on a 5-point Likert scale how strongly they would agree or disagree with its inclusion in dermoscopy training for primary care. Panelists were also able to propose wording modifications or suggest additional features. In the subsequent round, panelists rerated features that nearly reached consensus (positive responses from >60% but <70% of participating panelists) and rated additional features. Two formal rounds of features surveys were performed between December 2021 and February 2022.

On the conclusion of each round, all responses were deidentified, and data analyses were performed using REDCap and Microsoft Excel. Panelists received a summary of the preliminary results that reported the percentage of positive responses for each diagnosis. These results summaries were intended to inform panelists’ decisions in subsequent rounds.

Each specific item that reached final consensus for inclusion received positive responses (defined as selection of “strongly agree” or “agree” on the Likert scale) from >70% of participating panelists. This threshold criterion was derived from the MPWG-PLS’s consensus process that used a similar 2-phase modified Delphi method.21 Features that received >50% but <70% positive responses were not formally included in the final consensus statement but were labeled as “optional to include” for PCP-targeted dermoscopy training.

Panel Recruitment

Through known professional networks, 40 subject matter experts were invited to join the panel: 25 PCPs (23 family medicine physicians and 2 internal medicine physicians) who routinely use dermoscopy in clinical practice and 15 dermatologists. Of the 15 invited dermatologists, most are directly involved in dermoscopy education and skin cancer detection training for PCPs, and 2 previously worked in primary care.

At the beginning of each survey, panelists reviewed and acknowledged a consent statement. No monetary compensation for panel participation was offered. For both survey series, copies of the consent statement, survey instruments, and results summaries can be found in the online appendices.

Results

Panelist Demographics

Of the 40 active physicians invited to join the panel, 35 (87.5%) participated in the initial round (Table 1). Of these 35, 21 (60.0%, 19 family medicine physicians and 2 internal medicine physicians) were PCPs (76.2% response rate), and the remaining 14 (40.0%) were dermatologists (93.3% response rate). Sixteen of the initial panelists (45.7%) reported specializing in pigmented lesions, dermoscopy, or melanoma as an attending physician. Of these 16, 3 were PCPs (2 family medicine physicians and 1 internal medicine physician), while the remainder were dermatologists. A majority (62.9%) reported being directly involved in dermoscopy training for primary care, offering training in the clinic and/or through lectures.

Table 1.

Demographic Characteristics of Larger Expert Panel (n = 35 Participants in First Round)

Specialty (n = 35) Count %
Family medicine 19 54.3%
Internal medicine 2 5.7%
Medicine—pediatrics 0 0.0%
Dermatology 14 40.0%
Otder 0 0.0%
Dermoscopy use in clinical practice (n = 35) Count %
Yes 35 100%
No 0 0.0%
No. years of dermoscopy use in clinical practice (n = 35) Count %
0 to 1 year 0 0.0%
1 to 5 years 16 45.7%
6 to 10 years 10 28.6%
11 to 15 years 4 11.4%
15 + years 5 14.3%
Specialization in pigmented lesions, dermoscopy, or melanoma as an attending physician (n = 35) Count %
Yes 16 45.7%
No 19 54.3%
No. years of specialization in pigmented lesions, dermoscopy, or melanoma as an attending physician (n = 16) Count %
0 to 1 year 0 0.0%
1 to 5 years 7 43.8%
6 to 10 years 2 12.5%
11 to 15 years 4 25.0%
15 + years 3 18.8%
Direct involvement in dermoscopy training for primary care (n = 35) Count %
Yes 22 62.9%
No 13 37.1%
If directly involved in dermoscopy training for primary care, type of training offered* (n = 22) Count %
Dermoscopy training in clinic 18 81.8%
Dermoscopy training in a lecture format 15 68.2%
Other 3 13.6%
*

Multiple selections allowed, sum of percentages >100%.

Other delivery methods for dermoscopy training, as reported by panelists, included virtual training, e-learning, distance learning.

Over the course of the study, 5 PCPs were lost to follow-up or withdrew from the study. Of the 30 who completed the fifth and last round, 16 (53.3%, 14 family medicine physicians and 2 internal medicine physicians) were PCPs (76.2% retention rate), and 14 (46.7%) were dermatologists (100% retention rate).

Survey Results

The consensus process involved 2 successive survey series: (1) diagnoses, and (2) features. In the diagnoses survey series, panelists voted on a total of 51 diagnoses (Table 2). Of this total, 15 represented additional diagnoses written in by panelists, and 39 received >70% positive responses and reached final consensus for inclusion (13 in level 1 and 26 in level 2).

Table 2.

Dermoscopic Diagnoses by Lesion Category and Proficiency Standard

Category Level 1 (Foundational) Level 2 (Intermediate) Neither
Nonmelanocytic lesions
  • Hemangioma

  • Seborrheic keratosis

  • Dermatofibroma

  • Solar lentigo

  • Basal cell carcinoma

  • Squamous cell carcinoma

  • Actinic keratosis

  • Sebaceous hyperplasia

  • Pigmented actinic keratosis

  • Squamous cell carcinoma in situ

  • Keratoacanthoma

  • Angiokeratoma

  • Lichen planus-like keratosis

  • Ink spot lentigo

  • Clear cell acanthoma

  • Merkel cell carcinoma

  • Porokeratosois

  • Poroma

  • Xanthogranuloma

Benign melanocytic lesions
  • Overview of benign nevi patterns

  • Intradermal nevi

  • Blue nevi

  • Spitz nevi

  • Congenital melanocytic nevi

  • Recurrent/persistent nevi

  • Halo nevi

  • Combined nevi

Melanoma
  • Overview of melanoma patterns

  • Acral melanoma

  • Lentigo maligna melanoma

  • Melanoma of the nail

  • Amelanotic/hypomelanotic melanoma

  • Desmoplastic melanoma

  • Nevoid melanoma

  • Verrucous melanoma

Special sites Subungual hemorrhage
  • Dermoscopic features of the face

  • Benign patterns of acral nevi

  • Nevus of the nail

  • Lentigo of the nail

  • Talon noir

  • Nevi of the mucosa

  • Nevi of the mucocutaneous junction

Other
  • Verruca*

  • Scabies

  • Molluscum contagiosum*

  • Radiation tattoo*

  • Scars*

  • Venous lake*

  • Psoriasis

  • Atopic dermatitis

*

Suggested by the expert focus group to add onto the Melanoma Prevention Working Group-Pigmented Lesions Subcommittee consensus-based list for dermatology residents.

Suggested by a panelist during round 1 of the diagnoses survey series.

Suggested by a panelist during round 2 of the diagnoses survey series.

In the features survey series, panelists voted on the inclusion of different dermoscopic features for each included diagnosis. A summary of the features survey results—organized into the categories of nonmelanocytic lesions, benign melanocytic lesions, melanoma, special sites, and other diagnoses—is included in Tables 37. Of the 156 total features surveyed, 6 represented additional features written in by panelists, and 120 features received >70% positive responses and reached final consensus for inclusion (62 in level 1 and 58 in level 2). Certain features may have been excluded if they are rarely seen, challenging to discern, and/or of poor diagnostic value. Of note, 19 features (4 in level 1 and 15 in level 2) received >50% but <70% positive responses and thus did not reach final consensus. However, depending on the degree of interest and skill level of the educational cohort, these features may be added as a learning objective at the discretion of the curricular development team.

Table 3.

Dermoscopic Characteristics of Nonmelanocytic Lesions

Diagnosis (Level 1 or 2)
Feature included as a learning objective (>70% positive responses)
Round 1: % Positive Responses*
(n = 33)
Round 2: % Positive Responses*
(n = 30)
Hemangioma (level 1)
Red, blue-red, red-purple, or maroon lacunae/lagoons with white septae 72.7%
Blue-black coloring in lacunae (when thrombosed) in absence of other structures 72.7%
Seborrheic keratosis (level 1)
Milia-like cysts (cloudy or starry) and comedo-like openings 93.9%
“Fissures and ridges”/“gyri and sulci”/cerebriform pattern 93.9%
Moth-eaten (sharply demarcated) borders 87.9%
Fat fingers 78.8%
Fingerprint-like structures (parallel lines) 78.8%
Hairpin (looped) vessels 78.8%
Dermatofibroma (level 1)
Central scar-like white patch/depigmentation 100.0%
Fine/delicate surrounding/peripheral network-like structures 100.0%
Central shiny white lines/streaks under polarized dermoscopy 84.8%
 Ring-like globules 66.7% 60.0%
Solar lentigo (level 1)
Moth-eaten (sharply demarcated) borders 90.9%
Fingerprint-like structures (parallel lines) 90.9%
Homogenous light brown pigmentation 87.9%
Uniform brown perifollicular pigmentation 75.8%
 Network-like structures 63.6% 63.3%
Basal cell carcinoma (level 1)
Arborizing vessels 97.0%
Ulceration/erosion 93.9%
Leaf-like structures/areas 90.9%
Blue-gray ovoid nests 87.9%
Spoke-wheel-like structures/areas/concentric structures 87.9%
Multiple blue-gray dots and globules (buckshot scatter) 84.8%
Shiny white blotches and strands/structures under polarized dermoscopy 69.7% 76.7%
Short fine telangiectasias (superficial BCC) 69.7% 70.0%
Squamous cell carcinoma (level 1)
Yellow keratin mass/scale-crust 100.0%
Ulceration/blood spots/hemorrhage 93.9%
White circles (“keratin pearls”) 90.9%
Glomerular (coiled) vessels 90.9%
Hairpin vessels 78.8%
Rosettes 75.8%
Actinic keratosis (level 1)
Surface scale 97.0%
Rosettes 81.8%
Strawberry pattern (pink-red pseudonetwork ± fine wavy vessels [straight or coiled] surrounding hair follicles ± white circles with central yellow clod [targetoid hair follicles]) 78.8%
Sebaceous hyperplasia (level 2)
Pale yellow lobules (popcorn-like structures) around a central follicular opening 100.0%
Crown vessels, out of focus 90.9%
Pigmented actinic keratosis (level 2)
Surface scale 90.9%
Rosettes 75.8%
 Annular-granular pattern (gray dots around follicular openings) 66.7% ↓ 53.3%
 Red pseudonetwork 57.6%
 Patent/evident follicles 57.6%
Squamous cell carcinoma in situ (level 2)
Irregularly arranged glomerular (coiled)/dotted vessels 93.9%
Surface scale 87.9%
Keratoacanthoma (level 2)
Central keratin mass 93.9%
Hairpin (looped) or serpentine (linear-irregular) vessels, usually at the periphery, with white-yellow halo 87.9%
Angiokeratoma (level 2)
Red/purple/black (“dark”) lacunae 93.9%
Hemorrhagic crust 75.8%
Lichen planus-like keratosis (level 2)
Features of a lentigo or seborrheic keratosis in an area 72.7%
 Peppering (evenly spaced gray dots) 69.7% ↓ 63.3%
 Sharp cut-off borders (scalloped/moth-eaten) 69.7% ↓ 63.3%
 Coarse gray granularity 63.6% ↓ 53.3%
Ink spot lentigo (level 2)
Prominent dark homogenous (uniform) reticular network 93.9%
 Chicken-wire fence 63.6% ↓ 50.0%
*

% of panelists who indicated on a 5-point Likert scale that they “strongly agree” (5) or “agree” (4) with the feature being included in dermoscopy training for primary care providers.

Suggested by a panelist during round 1 of the features survey series.

Abbreviations: BCC, basal cell carcinoma; SCCIS, squamous cell carcinoma in situ (Bowen’s disease).

Table 7.

Dermoscopic Characteristics of Other Diagnoses, Including Skin Infections and Infestations

Diagnosis (Level 1 or 2)
Feature included as a learning objective (>70% positive responses)
Round 1: % Positive Responses*
(n = 33)
Round 2: % Positive Responses*
(n = 30)
Verruca (level 1)
 Papilliform structures 93.9%
 Tiny red-black dots (papillary capillaries) 90.9%
Scabies (level 1)
 Delta-wing jet with contrail sign (small dark brown triangular structure located at the end of whitish structureless curved/wavy lines) 90.9%
Molluscum contagiosum (level 2)
 Central pore or umbilication 93.9%
 Polylobular white-yellow amorphous structures 81.8%
 Linear or branched vessels (red corona)/crown vessels 63.6% ↓ 63.3%
Radiation tattoo (level 2)
 Homogenous blue or black coloration 84.8%
Scars (level 2)
 White depigmentation 72.7%
Venous lake (level 2)
 Homogenous purple/blue/red coloration ± globules/clods 93.9%
Psoriasis (level 2)
 Red or pink color with white scales/light-red background 75.8%
 Dotted vessels in a regular distribution 72.7%
*

% of panelists who indicated on a 5-point Likert scale that they “strongly agree” (5) or “agree” (4) with the feature being included in dermoscopy training for primary care providers.

The online appendices contain the final list of diagnoses and their associated features, organized into levels 1 and 2 based on Delphi agreement. For each associated feature, dermoscopy users may customarily refer to different nomenclatures to describe the same pattern. In this study, the exact wording for each feature was considered less important than the described feature itself.

Discussion

Through a modified Delphi exercise, an expert panel that comprised family medicine physicians, internal medicine physicians, and dermatology specialists achieved consensus on proficiency standards for PCPs learning or using dermoscopy. This collaboration between primary care and dermatology reflects a growing national partnership that has been emerging as an important strategy for skin cancer prevention and detection, especially in rural areas.

Given the range of interest in dermoscopy among PCPs, the consensus process generated 2 levels of proficiency standards. The focus of level 1 (foundational proficiency) is training in the basic skills required to differentiate between benign and malignant lesions under dermoscopy. As expected, level 1 teaches an overview of nevi patterns and melanoma patterns as well as classic features for keratinocyte carcinomas, namely BCC and SCC.

Level 1 also contains common benign diagnoses that closely align with the triage amalgamated dermoscopy algorithm (TADA).27,28 This diagnostic aid trains learners to first search for specific features of common benign diagnoses (ie, angioma/hemangioma, seborrheic keratosis, dermatofibroma).29,30 In suspicious lesions, learners next evaluate for characteristic features of malignant diagnoses that would warrant biopsy, excision, or referral to a specialist.31 Training programs based on TADA have been shown to improve the sensitivity for skin cancer detection compared with baseline.2932 Given the proven effectiveness of TADA in training PCPs and novices,33 PCP-targeted dermoscopy education based on level 1 may begin with TADA and then continue to the other level 1 diagnoses.

Extending beyond level 1, level 2 is intended for more experienced PCPs who desire more advanced dermoscopy skills. Compared with those in level 1, diagnoses in level 2 are mostly considered less common in the general population and/or more challenging to discern (eg, pigmented actinic keratosis, lichen planus-like keratosis). Level 2 also incorporates different types of melanoma (eg, lentigo maligna melanoma, amelanotic/hypomelanotic melanoma) and benign nevi (eg, blue nevi, acral nevi) and demonstrates a broader utility of dermoscopy in the identification of other diagnoses frequently encountered by PCPs (eg, molluscum contagiosum, psoriasis).

With the exception of 1 diagnosis that required 2 rounds of feedback (ie, scabies), all level 1 diagnoses were deemed “foundational” by the panel during the very first round of voting, demonstrating strong consensus on the diagnoses reflective of a basic yet practical skillset for PCPs. Subsequent rounds focused on sorting between level 1 and 2 diagnoses and identifying diagnoses that should be excluded from either level. For instance, the decision-making process for lichen planus-like keratosis required 3 rounds of voting before assigning the diagnosis to level 2.

The outcome of this PCP-focused consensus effort differs in some ways from the proficiency standard developed by the MPWG-PLS for dermatology residents.21 In addition to assigning diagnoses to level 1 or 2, this panel approved the inclusion of additional diagnoses and excluded clear cell acanthoma from either level. Of the 15 total additional diagnoses suggested by panelists, 1 (ie, verruca) reached consensus for inclusion in level 1, and 4 (ie, ink spot lentigo, halo nevi, talon noir, psoriasis) in level 2. The expert focus group also removed simple lentigo from the list due to its overlap with solar lentigo. With the exception of psoriasis (level 2), all other diagnoses excluded from the foundational proficiency standard for dermatology residents (eg, poroma, Merkel cell carcinoma, nevoid melanoma, desmoplastic melanoma) were likewise excluded from the foundational and intermediate proficiency standards for PCPs. The mutual exclusion of these extremely rare and/or challenging diagnoses by this panel serves to validate the results of this consensus process.

This consensus statement will contribute to the development of effective educational interventions that teach expert-approved learning objectives and have content validity.24 It may also serve as the basis of formal proficiency certification or continuing medical education credit for PCPs. Yet, the application of this consensus statement comes with an important caveat: educators and learners alike are strongly discouraged from approaching dermoscopy training as a process akin to the rote memorization of a list of diagnoses and features. Efficient interpretation of dermoscopic images relies heavily on pattern recognition skills34 and “fast thinking.”35 Though the educational science for dermoscopy education remains to be further developed, active learning strategies, such as visual perceptual training36 or deliberate practice,37 are generally more effective than passive instructional approaches. Future studies will explore the application of this consensus statement to dermoscopy educational interventions for PCPs. Further research is also needed to determine best practices for dermoscopy proficiency assessments.

Conclusions

Dermoscopy is a valuable tool that assists clinicians in discriminating malignant from benign skin lesions. For PCPs who treat skin conditions and evaluate skin lesions, dermoscopy training improves sensitivity for skin cancer diagnosis. However, 1 of the obstacles to developing a standardized dermoscopy curriculum for PCPs has been the lack of consensus on appropriate learning objectives. To PCPs using dermoscopy in clinical practice, this study provides meaningful insight into the diagnoses and features that an expert panel considers important to recognize, especially in the course of identifying skin cancer.

The consensus statement generated by this modified Delphi study will inform future dermoscopy training programs designed to support early skin cancer detection by PCPs. Through the dissemination of a standardized dermoscopy curriculum, the dermatoscope may become increasingly recognized as a valuable component of the PCP’s toolbox alongside other commonly used medical instruments such as the ophthalmoscope, otoscope, and stethoscope.38 The ultimate goal of these dermoscopy training initiatives would be to decrease patient morbidity and mortality from skin cancer, especially in regions without convenient access to dermatology specialists.

Supplementary Material

1

Table 4.

Dermoscopic Characteristics of Benign Melanocytic Lesions

Diagnosis (Level 1 or 2)
Feature included as a learning objective (>70% positive responses)
Round 1: % Positive Responses*
(n = 33)
Round 2: % Positive Responses*
(n = 30)
Overview of benign nevi patterns (level 1)
Diffuse reticular network 100.0%
Peripheral reticular network with central hypopigmentation 100.0%
Peripheral reticular network with central hyperpigmentation 100.0%
Globular pattern 100.0%
Patchy reticular network 97.0%
Homogenous (tan, brown, blue, or pink) 93.9%
Peripheral reticular network with central globules 90.9%
Central network with evenly distributed peripheral globules 87.9%
Symmetric multicomponent pattern 75.8%
 Symmetric two-component pattern 69.7% ↓ 60.0%
Intradermal nevi (level 1)
Comma-shaped (curved) vessels 93.9%
Homogenous (structureless) brown/tan/pink pigmentation 93.9%
Peripheral network 72.7%
Globules 87.9%
Blue nevi (level 2)
Homogenous blue/blue-gray pigmentation 100.0%
Well-circumscribed lesion 93.9%
Spitz nevi (level 2)
Starburst pattern with tiered globules/streaks and regularly spaced pseudopods at the periphery(radial streaming) 87.9%
Vascular pattern (pink homogenous with dotted vessels) 75.8%
Congenital melanocytic nevi (level 2)
Cobblestone pattern/globular pattern 93.9%
Reticular network 90.9%
Homogenous background pigmentation 87.9%
Hypertrichosis 78.8%
 Perifollicular hyper-/hypopigmentation 69.7% ↓ 60.0%
Recurrent/persistent nevi (level 2)
Pigment within the scar, not extending beyond 81.8%
Halo nevi (level 2)
Encircling/surrounding depigmentation/pallor 93.9%
Central reticulation with peripheral white depigmentation 78.8%
Benign nevi patterns, globular, homogenous 78.8%
*

% of panelists who indicated on a 5-point Likert scale that they “strongly agree” (5) or “agree” (4) with the feature being included in dermoscopy training for primary care providers.

Table 5.

Dermoscopic Characteristics of Melanomas

Diagnosis (Level 1 or 2)
Feature included as a learning objective (>70% positive responses)
Round 1: % Positive Responses*
(n = 33)
Round 2: % Positive Responses*
(n = 30)
Overview of melanoma patterns (level 1)
Blue structures (blue-white veil, blue-gray structures) 100.0%
Shiny white lines/structures (crystalline structures) 100.0%
Atypical pigment network 97.0%
Atypical/irregular streaks (radial streaming, pseudopods) 97.0%
Atypical/irregular dots/globules 93.9%
Regression structures (white scar-like area and/or peppering) 93.9%
Negative pigment network 87.9%
Atypical vascular pattern/structures, polymorphous vessels (2 + types of blood vessels) 87.9%
Peripheral brown/tan structureless area 78.8%
Angulated lines (extrafacial)/polygons/zig-zag pattern 75.8%
Atypical/off-center blotch(es) 69.7% ↑ 90.0%
Acral melanoma (level 2)
Parallel ridge pattern 93.9%
Ulceration 90.9%
Irregular diffuse pigmentation or blotch 84.8%
Multicomponent pattern, asymmetry of structures/colors 84.8%
Atypical fibrillar pattern 72.7%
Neovascularization, milky red 72.7%
Lentigo maligna melanoma (level 2)
Annular-granular pattern (gray dots around follicular openings) 90.9%
Asymmetric pigmentation around follicular openings/asymmetric follicular openings 87.9%
Rhomboidal structures (angulated lines)/zig-zag pattern 81.8%
Dark blotches ± obliterated hair follicles 75.8%
 Circle within a circle (isobar) 60.6% ↓ 56.7%
Melanoma of the nail (level 2)
Pigmentation of periungual skin (micro-Hutchinson’s sign) 90.9%
Triangular shape of pigment band (band diameter wider at proximal end) 87.9%
Longitudinal brown/black broken lines with irregular spacing, width, coloration, or parallelism 81.8%
Band width >3 mm or two thirds of nail plate width 78.8%
 Brown to black dots/globules associated with longitudinal lines 60.6% ↓ 50.0%
Amelanotic/hypomelanotic melanoma (level 2)
Milky red areas 81.8%
Shiny white lines (crystalline structures) 81.8%
Atypical vascular pattern, polymorphous vessels (2 + types of blood vessels) 81.8%
Scar-like depigmentation 75.8%
*

% of panelists who indicated on a 5-point Likert scale that they “strongly agree” (5) or “agree” (4) with the feature being included in dermoscopy training for primary care providers.

Table 6.

Dermoscopic Characteristics of Benign Diagnoses at Special Sites

Diagnosis (Level 1 or 2)
Feature included as a learning objective (>70% positive responses)
Round 1: % Positive Responses*
(n = 33)
Round 2: % Positive Responses*
(n = 30)
Subungual hemorrhage (level 1)
Well-circumscribed red-black dots or blotches/blood spots 90.9%
Discontiguous with the cuticle (not connected to the proximal nailfold or edge of nail) 87.9%
Distal streaks of red-brown coloration (“filamentous” distal end) 81.8%
 Homogenous red/purple/black coloration without melanin granules 69.7% ↓ 60.0%
Dermoscopic features of the face (level 2)
Pseudonetwork 78.8%
Benign patterns of acral nevi (level 2)
Parallel furrow pattern (with pattern variations including single line, double line, single dotted line, double dotted line) 93.9%
Lattice-like pattern 87.9%
Fibrillar pattern (soles only) 84.8%
Homogenous pattern 75.8%
 Peas-in-a-pod pattern (parallel furrow 1 globules on ridges) (acral congenital melanocytic nevi) 69.7% ↓ 56.7%
Nevus of the nail (level 2)
Uniform band thickness, color, and spacing with parallel band configuration and unbroken lines 87.9%
Homogenous brown background coloration 84.8%
Lentigo of the nail (level 2)
Homogenous gray band or lines ± gray background 78.8%
 Regular light-brown lines 60.0%
Talon noir (level 2)
Homogenous red-brown coloration 78.8%
 Cracks (lightning bolt sign) 51.5%
*

% of panelists who indicated on a 5-point Likert scale that they “strongly agree” (5) or “agree” (4) with the feature being included in dermoscopy training for primary care providers.

Suggested by a panelist during round 1 of the dermoscopic features survey series.

Feature did not undergo a revote in round 2 due to original threshold criteria for a revote being <70% but >60% positive responses.

Funding:

This project was supported in part by the generous philanthropic contributions of the Lyda Hill Foundation to the University of Texas MD Anderson Cancer Center Moon Shots Program. The funding source was not involved in the design or conduct of the study; the collection, management, analysis, or interpretation of the data; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.

The research team wishes to acknowledge Dr. Lauren Fried for her guidance on the study design.

Footnotes

Conflict of interest: None.

Prior presentation: A summary of this original work was presented as a medical student poster by Ms. Tiffaney Tran at the annual American Dermoscopy Meeting in St. George, Utah, on July 1, 2022. This work has otherwise not been previously posted or published elsewhere, nor is it under consideration for publication elsewhere.

To see this article online, please go to: http://jabfm.org/content/36/1/25.full.

References

  • 1.Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA A Cancer J Clinicians 2022;72: 7–33. [DOI] [PubMed] [Google Scholar]
  • 2.Howlader NN, Krapcho M, Miller D, et al. editors. SEER cancer statistics review, 1975–2016 [Internet].2019. [cited 2021 July 1]. Available from: https://seer.cancer.gov/csr/1975_2016/. [Google Scholar]
  • 3.Glazer AM, Farberg AS, Winkelmann RR, Rigel DS. Analysis of trends in geographic distribution and density of US dermatologists. JAMA Dermatol 2017;153:322–5. [DOI] [PubMed] [Google Scholar]
  • 4.Vaidya T, Zubritsky L, Alikhan A, Housholder A. Socioeconomic and geographic barriers to dermatology care in urban and rural US populations. J Am Acad Dermatol 2018;78:406–8. [DOI] [PubMed] [Google Scholar]
  • 5.Wu X, Marchetti MA, Marghoob AA. Dermoscopy: not just for dermatologists. Melanoma Manag 2015; 2:63–73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Losina E, Walensky RP, Geller A, et al. Visual screening for malignant melanoma: a cost-effectiveness analysis. Arch Dermatol 2007;143:21–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Marghoob NG, Liopyris K, Jaimes N. Dermoscopy: a review of the structures that facilitate melanoma detection. J Am Osteopath Assoc 2019;119:380–90. [DOI] [PubMed] [Google Scholar]
  • 8.Vestergaard ME, Macaskill P, Holt PE, Menzies SW. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol 2008;159:669–76. [DOI] [PubMed] [Google Scholar]
  • 9.Dinnes J, Deeks JJ, Grainge MJ, et al. Visual inspection for diagnosing cutaneous melanoma in adults. Cochrane Database Syst Rev 2018;12:CD013194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Prasad S, Black S, Chen HW, et al. Beliefs and barriers to care of primary care practitioners toward melanoma screening and education in rural Texas. J Am Acad Dermatol. Forthcoming 2022. [DOI] [PubMed] [Google Scholar]
  • 11.Verhoeven EW, Kraaimaat FW, van Weel C, et al. Skin diseases in family medicine: prevalence and health care use. Ann Fam Med 2008;6:349–54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Perera E, Xu C, Manoharan S. Real-life teledermatology cases. In: Soyer HP, Binder M, Smith AC, Wurm EMT, editors. Telemedicine in dermatology. Springer Science & Business Media; 2012. p. 123–9. [Google Scholar]
  • 13.Westerhoff K, McCarthy WH, Menzies SW. Increase in the sensitivity for melanoma diagnosis by primary care physicians using skin surface microscopy. Br J Dermatol 2000;143:1016–20. [DOI] [PubMed] [Google Scholar]
  • 14.Argenziano G, Puig S, Zalaudek I, et al. Dermoscopy improves accuracy of primary care physicians to triage lesions suggestive of skin cancer. J Clin Oncol 2006;24:1877–82. [DOI] [PubMed] [Google Scholar]
  • 15.Menzies SW, Emery J, Staples M, et al. Impact of dermoscopy and short-term sequential digital dermoscopy imaging for the management of pigmented lesions in primary care: a sequential intervention trial. Br J Dermatol 2009;161:1270–7. [DOI] [PubMed] [Google Scholar]
  • 16.Koelink CJ, Vermeulen KM, Kollen BJ, et al. Diagnostic accuracy and cost-effectiveness of dermoscopy in primary care: a cluster randomized clinical trial. J Eur Acad Dermatol Venereol 2014;28:1442–9. [DOI] [PubMed] [Google Scholar]
  • 17.De Bedout V, Williams NM, Muñoz AM, et al. Skin cancer and dermoscopy training for primary care physicians: a pilot study. Dermatol Pract Concept 2021;11:e2021145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Pokhrel PK, Helm MF, Greene A, Helm LA, Partin M. Dermoscopy in primary care. Prim Care 2022;49:99–118. [DOI] [PubMed] [Google Scholar]
  • 19.Posada EL, Lauck KC, Tran T, Krause KJ, Nelson KC. Educational interventions to support primary care provider performance of diagnostic skin cancer examinations: a systematic literature review. J Cancer Educ 2022;1–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Najmi M, Brown AE, Harrington SR, Farris D, Sepulveda S, Nelson KC. A systematic review and synthesis of qualitative and quantitative studies evaluating provider, patient, and health care system-related barriers to diagnostic skin cancer examinations. Arch Dermatol Res 2022; 314:329–40. [DOI] [PubMed] [Google Scholar]
  • 21.Fried LJ, Tan A, Berry EG, et al. Dermoscopy proficiency expectations for US dermatology resident physicians: results of a modified Delphi survey of pigmented lesion experts. JAMA Dermatol 2021; 157:189–97. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Dalkey NC, Helmer O. An experimental application of the DELPHI method to the use of experts. Manag Sci 1963;9:458–67. [Google Scholar]
  • 23.Dalkey NC. The Delphi method: an experimental study of group opinion. RAND Corporation; 1969. [Google Scholar]
  • 24.Rusticus S Content validity. In: Michalos AC, ed. Encyclopedia of quality of life and well-being research. Springer; Netherlands; 2014. p. 1261–2. [Google Scholar]
  • 25.Dermoscopedia [Internet]. International Dermoscopy Society; 2021. [accessed 1 Nov 2021]. Available from: https://dermoscopedia.org/Main_Page. [Google Scholar]
  • 26.Kittler H, Marghoob AA, Argenziano G, et al. Standardization of terminology in dermoscopy/dermatoscopy: results of the third consensus conference of the International Society of Dermoscopy. J Am Acad Dermatol 2016;74:1093–106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Rogers T, Marino ML, Dusza SW, et al. A clinical aid for detecting skin cancer: the triage amalgamated dermoscopic algorithm (TADA). J Am Board Fam Med 2016;29:694–701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Jaimes N, Marghoob AA. Triage amalgamated dermoscopic algorithm. J Am Acad Dermatol 2020; 82:1551–2. [DOI] [PubMed] [Google Scholar]
  • 29.Seiverling EV, Ahrns HT, Greene A, et al. Teaching benign skin lesions as a strategy to improve the triage amalgamated dermoscopic algorithm (TADA). J Am Board Fam Med 2019;32:96–102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Sawyers EA, Wigle DT, Marghoob AA, Blum A. Dermoscopy training effect on diagnostic accuracy of skin lesions in Canadian family medicine physicians using the triage amalgamated dermoscopic algorithm. Dermatol Pract Concept 2020;10:e2020035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Susong JR, Ahrns HT, Daugherty A, Marghoob AA, Seiverling EV. Evaluation of a virtual basic dermatology curriculum for dermoscopy by using the triage amalgamated dermoscopic algorithm for novice dermoscopists. J Am Acad Dermatol 2020;83:590–2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Seiverling E, Ahrns H, Stevens K, et al. Dermoscopic lotus of learning: implementation and dissemination of a multimodal dermoscopy curriculum for primary care. J Med Educ Curric Dev 2021;8:2382120521989983–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Cyr PR, Craig W, Ahrns H, Stevens K, Wight C, Seiverling E. Teaching skin cancer detection to medical students using a dermoscopic algorithm. STFM PRiMER 2021;5:6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Kellman PJ, Garrigan P. Perceptual learning and human expertise. Phys Life Rev 2009;6:53–84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Gronchi G, Giovannelli F. Dual process theory of thought and default mode network: a possible neural foundation of fast thinking. Front Psychol 2018;9:1237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Rimoin L, Altieri L, Craft N, Krasne S, Kellman PJ. Training pattern recognition of skin lesion morphology, configuration, and distribution. J Am Acad Dermatol 2015;72:489–95. [DOI] [PubMed] [Google Scholar]
  • 37.Ericsson KA. Acquisition and maintenance of medical expertise: a perspective from the expert-performance approach with deliberate practice. Acad Med 2015;90:1471–86. [DOI] [PubMed] [Google Scholar]
  • 38.Lallas A, Argenziano G. Dermatoscope—the dermatologist’s stethoscope. Indian J Dermatol Venereol Leprol 2014;80:493–4. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1

RESOURCES